Testicular germ cell tumours are relatively rare but they are the most common cause of cancer in men between the age of 15 and 35 years. They are the well treated type of solid tomours and serve as a model treatment for many multimodal malignancies. Well defined clinical guidelines are present for the diagnosis and the treatment of nonseminomatous germ cell tumour. However, there is not any standardization especially for follow-up protocol. In recent years, the incidence of testicular cancer is rising especially in European countries. The cause of the increased incidence and etiologic factors is still uncertain. Managing patients with clinical stage I nonseminomatous germ cell tumour is a complex business requiring multidisciplinary teamwork and multiple clinical scenarios. The aim of this article is to assess the clinical stage I nonseminomatous germ cell tumours in the light of the guidelines and current data.

Keywords: Stage I, nonseminomatous germ cell tumour, surveillance, chemotherapy, retroperitoneal lymph node dissection, risk-adapted treatment